Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06009029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Name: SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) — clinical trial record (NCT06009029)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorPeking University Third Hospital

Started2023-08

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 24, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Peking University Third Hospital

219 trials monitored

See 3 trials at risk

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).

Trial Details

NCT Number	NCT06009029
Lead Sponsor	Peking University Third Hospital
Conditions	Locally Advanced Pancreatic Cancer
Enrollment	96 participants
Start Date	2023-08
Primary Completion	2026-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2023-08-24